Tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients
Tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients
Abstract ObjectiveThis single-center retrospective study evaluated the use of tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients (KTRs) during the omicron wave. MethodsKTRs were deemed at high risk for moderate-to-severe COVID-19 in presence of at least one comorbidity (age >60 years, diabetes, obesity, or cardiovascular disease) associated with a weak humoral response (<264 BAU/mL). All other KTRs were considered at low risk. The two groups were stratified according to the administration of tixagevimab-cilgavimab and compared in terms of COVID-19-related hospitalization, oxygen need, ICU admission, and mortality. ResultsOf the 61 KTRs at high risk, 26 received tixagevimab-cilgavimab. COVID-19-related hospitalizations (3.8% versus 34%, p=0.006) and oxygen need (3.8% versus 23%, p=0.04) were significantly less frequent in patients who received tixagevimab-cilgavimab. In addition, non-significant trends towards a lower number of ICU admissions (3.8% versus 14.3% p=0.17) and deaths (0 versus 3, p=0.13) were observed after administration of tixagevimab-cilgavimab. Ten of the 73 low-risk KTRs received tixagevimab-cilgavimab, and no significant clinical benefit was observed in this subgroup. ConclusionEarly administration of tixagevimab-cilgavimab may be clinically useful in high-risk KTRs with COVID-19; however, no major benefit was observed for low-risk patients.
Pszczolinski Romain、Caillard Sophie、Benotmane Ilies、Olagne J¨|r?me、Cognard No?lle、Braun-Parvez Laura、Vargas Gabriela Gautier、Perrin Peggy、Heibel Francoise、Fafi-Kremer Samira、Moulin Bruno、Keller Nicolas、Martzloff Jonas
Department of Nephrology Dialysis and Transplantation, Strasbourg University HospitalDepartment of Nephrology Dialysis and Transplantation, Strasbourg University Hospital||Inserm UMR S1109 Labex Transplantex, F¨|d¨|ration de M¨|decine Translationnelle, Strasbourg UniversityDepartment of Nephrology Dialysis and Transplantation, Strasbourg University Hospital||Inserm UMR S1109 Labex Transplantex, F¨|d¨|ration de M¨|decine Translationnelle, Strasbourg UniversityDepartment of Nephrology Dialysis and Transplantation, Strasbourg University HospitalDepartment of Nephrology Dialysis and Transplantation, Strasbourg University HospitalDepartment of Nephrology Dialysis and Transplantation, Strasbourg University HospitalDepartment of Nephrology Dialysis and Transplantation, Strasbourg University HospitalDepartment of Nephrology Dialysis and Transplantation, Strasbourg University HospitalDepartment of Nephrology Dialysis and Transplantation, Strasbourg University HospitalInserm UMR S1109 Labex Transplantex, F¨|d¨|ration de M¨|decine Translationnelle, Strasbourg University||Department of Virology, Strasbourg University HospitalDepartment of Nephrology Dialysis and Transplantation, Strasbourg University Hospital||Inserm UMR S1109 Labex Transplantex, F¨|d¨|ration de M¨|decine Translationnelle, Strasbourg UniversityDepartment of Nephrology Dialysis and Transplantation, Strasbourg University HospitalDepartment of Nephrology Dialysis and Transplantation, Strasbourg University Hospital
临床医学内科学医药卫生理论
SARS-CoV-2kidney transplant recipientsimmunocompromised patientsmonoclonal antibodiestixagevimab-cilgavimab
Pszczolinski Romain,Caillard Sophie,Benotmane Ilies,Olagne J¨|r?me,Cognard No?lle,Braun-Parvez Laura,Vargas Gabriela Gautier,Perrin Peggy,Heibel Francoise,Fafi-Kremer Samira,Moulin Bruno,Keller Nicolas,Martzloff Jonas.Tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients[EB/OL].(2025-03-28)[2025-04-27].https://www.medrxiv.org/content/10.1101/2022.09.30.22280568.点此复制
评论